

# UNITED STATE DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

	APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR			ATTORNEY DOCKET NO.
	09/075,375	05/07/98	YAMAMOTO		H	CGNE119-2US
Γ	CALGENE LLC 1920 FIFTH STREET		HM22/0727	٦	<b>EXAMINER</b> ZAGHMOUT, O	
					ART UNIT	PAPER NUMBER
	DAVIS CA S	)5616			1638	10
					DATE MAILED:	07/27/81

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner of Patents and Trademarks** 

### Office Action Summary

Application No. 09/075,375

Applicant(s)

\_\_\_\_

Yamamoto et al.

Examiner

Ousama Zaghmout

Group Art Unit 1638



Responsive to communication(s) filed on Jun 5, 2000	
☑ This action is <b>FINAL</b> .	
Since this application is in condition for allowance except for in accordance with the practice under Ex parte Quayle, 1935	C.D. 11; 453 O.G. 213.
A shortened statutory period for response to this action is set to s longer, from the mailing date of this communication. Failure to application to become abandoned. (35 U.S.C. § 133). Extension 37 CFR 1.136(a).	o respond within the period for response will cause the
Disposition of Claims	
	is/are pending in the application.
Of the above, claim(s)	is/are withdrawn from consideration.
☐ Claim(s)	
X Claim(s) 3-5 and 9-11	
Claim(s)	is/are objected to.
☐ Claims	are subject to restriction or election requirement.
<ul> <li>☐ See the attached Notice of Draftsperson's Patent Drawing</li> <li>☐ The drawing(s) filed on is/are objected</li> <li>☐ The proposed drawing correction, filed on</li> <li>☐ The specification is objected to by the Examiner.</li> <li>☐ The oath or declaration is objected to by the Examiner.</li> </ul>	ed to by the Examiner.
Priority under 35 U.S.C. § 119  Acknowledgement is made of a claim for foreign priority of the CERTIFIED copies of received.  received in Application No. (Series Code/Serial Num	the priority documents have been
received in this national stage application from the *Certified copies not received:	
<ul> <li>Acknowledgement is made of a claim for domestic priorit</li> </ul>	y under 35 U.S.C. § 119(e).
Attachment(s)  Notice of References Cited, PTO-892 Information Disclosure Statement(s), PTO-1449, Paper Notice of Draftsperson's Patent Drawing Review, PTO-94 Notice of Informal Patent Application, PTO-152	

--- SEE OFFICE ACTION ON THE FOLLOWING PAGES ---

Serial Number: 09/075,375

Art Unit: 1638

### Status of Application

I. The Group and/or Art Unit location of your application in the PTO has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Group Art Unit 1638.

II. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

III. The amendment filed 06/05/2000 as been received and entered (Paper 14).

Status of the claims:

Claim 3 has been amended.

Claims 3-5, 9-11 are pending.

IV. In the Figures, there is no Figure 8A, 86 or 8C.

The Figures should be numbered 8A, 8B, 8C to agree with the Brief Description of Drawings. Figures 1-4 Should be labeled 1A, 1B, 1C, etc. and the Brief Description of Drawings amended accordingly. A description of Figure 4B should be added.

## **DOUBLE PATENT REJECTIONS**

The rejection of Claims 3-5, 9-11 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-18 of U.S. Patent No. 6,015,939 is

Serial Number: 09/075,375

Art Unit: 1638

maintained because the terminal disclaimer was not acceptable since it was not signed by Attorney of record.

An attorney or agent, not of record, is not authorized to sign a terminal disclaimer in the capacity as an attorney or agent acting in a representative capacity as provided by 37 CFR 1.34 (a). See 37 CFR 1.321(b) and/or (c).

It would be acceptable for a person, other than a recognized officer, to execute a terminal disclaimer, <u>provided</u> the record for the application includes a statement that the person is empowered to sign terminal disclaimers and/or act on behalf of the organization.

Accordingly, a new terminal disclaimer which includes the above empowerment statement will be considered to be executed by an appropriate official of the assignee. A separately filed paper referencing the previously filed terminal disclaimer and containing a proper empowerment statement would also be acceptable.

#### Conclusion

Claims 3-5, 9-11 are deemed free of the prior art given the failure of the prior art to teach or suggest the particularly claimed DNA sequence and their usage in transformation experiments.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire

THREE MONTHS from the mailing date of this action. In the event a first reply is filed

Serial Number: 09/075,375

Art Unit: 1638

within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Page 5

Serial Number: 09/075,375

Art Unit: 1638

### **Future Correspondence**

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Ousama M-Faiz Zaghmout whose telephone number is (703) 308-9438. The Examiner can normally be reached Monday through Friday from 7:30 am to 5:00 pm (EST).

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Paula Hutzell Ph.D, can be reached on (703) 308-4310. The fax phone number for the group is (703) 305-3014.

Any inquiry of a general nature or relating to the status of this application should be directed to THE MATRIX CUSTOMER SERVICE CENTER whose telephone number is (703) 308-0196.

Ousama M-Faiz Zaghmout Ph.D.

August 22, 2000